Pediatric skull inflammatory myofibroblastic tumor: a rare case report and literature review.
Anaplastic Lymphoma Kinase (ALK) expression
Craniofacial
Inflammatory Myofibroblastic Tumors (IMT)
Pediatric skull lesion
Journal
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
ISSN: 1433-0350
Titre abrégé: Childs Nerv Syst
Pays: Germany
ID NLM: 8503227
Informations de publication
Date de publication:
25 Jun 2024
25 Jun 2024
Historique:
received:
16
04
2024
accepted:
19
06
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
25
6
2024
Statut:
aheadofprint
Résumé
Inflammatory myofibroblastic tumors (IMTs) represent rare neoplasms, particularly infrequent in the pediatric skull. We present a novel case of a newborn male with a 5 cm right temporal mass and discuss current diagnostic and treatment options for IMTs. A multidisciplinary effort to surgically remove the lesion was successful, and the patient's skull defect healed without neurological deficits. The etiology of IMTs remains elusive, with proposed associations with chromosomal mutations in the anaplastic lymphoma kinase (ALK) gene. Surgical excision remains the primary treatment for IMTs. Promising pharmacological treatments, like Crizotinib, warrant further research into understanding potential alternatives in IMT management.
Identifiants
pubmed: 38918263
doi: 10.1007/s00381-024-06512-7
pii: 10.1007/s00381-024-06512-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Jo VY, Fletcher CD (2014) WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology 46(2):95–104. https://doi.org/10.1097/PAT.0000000000000050
doi: 10.1097/PAT.0000000000000050
pubmed: 24378391
National Cancer Institute. Inflammatory myofibroblastic tumor. National Cancer Institute, Bethesda. [cited 2023 November 27]
Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, Borinstein SC, Ross JS, Stephens PJ, Miller VA, Coffin CM (2014) Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 4(8):889–895. https://doi.org/10.1158/2159-8290.CD-14-0377
doi: 10.1158/2159-8290.CD-14-0377
pubmed: 24875859
pmcid: 4125481
Reinhart S, Trachsel Y, Fritz C, Wagner U, Bode-Lesniewska B, John H, Pless M (2020) Inflammatory myofibroblastic tumor of the bladder with FN1-ALK gene fusion: different response to ALK inhibition. Urology 146:32–35. https://doi.org/10.1016/j.urology.2020.09.026
doi: 10.1016/j.urology.2020.09.026
pubmed: 33007314
Cantera JE, Alfaro MP, Rafart DC et al (2015) Inflammatory myofibroblastic tumours: a pictorial review. Insights Imaging 6(1):85–96. https://doi.org/10.1007/s13244-014-0370-0
doi: 10.1007/s13244-014-0370-0
pubmed: 25519466
Tao J, Zhou ML, Zhou SH (2015) Inflammatory myofibroblastic tumors of the head and nec. Int J Clin Exp Med 8(2):1604–1610
pubmed: 25932089
pmcid: 4402736
Soyer T, Talim B, Karnak İ et al (2017) Surgical treatment of childhood inflammatory myofibroblastic tumors. Eur J Pediatr Surg 27(4):319–323. https://doi.org/10.1055/s-0036-1593380
doi: 10.1055/s-0036-1593380
pubmed: 27699733
Kovach SJ, Fischer AC, Katzman PJ et al (2006) Inflammatory myofibroblastic tumors. J Surg Oncol 94(5):385–391. https://doi.org/10.1002/jso.20516
doi: 10.1002/jso.20516
pubmed: 16967468
Da M, Qian B, Mo X et al (2021) Inflammatory myofibroblastic tumors in children: a clinical retrospective study on 19 cases. Front Pediatr 9:543078. https://doi.org/10.3389/fped.2021.543078
doi: 10.3389/fped.2021.543078
pubmed: 34307241
pmcid: 8295553
Siemion K, Reszec-Gielazyn J, Kisluk J, Roszkowiak L, Zak J, Korzynska A (2022) What do we know about inflammatory myofibroblastic tumors? – A systematic review. Adv Med Sci 67(1):129–138. https://doi.org/10.1016/j.advms.2022.02.002
doi: 10.1016/j.advms.2022.02.002
pubmed: 35219201
Raitio A, Losty PD (2024) Treatment and outcomes in pediatric inflammatory myofibroblastic tumors – A systematic review of published studies. Eur J Surg Oncol 50(7):108388. https://doi.org/10.1016/j.ejso.2024.108388
doi: 10.1016/j.ejso.2024.108388
pubmed: 38713995
Kube S, Vokuhl C, Dantonello T et al (2018) Inflammatory myofibroblastic tumors—a retrospective analysis of the cooperative weichteilsarkom studiengruppe. Pediatr Blood Cancer 65(6). https://doi.org/10.1002/pbc.27012
Casanova M, Brennan B, Alaggio R et al (2020) Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). Eur J Cancer 127:123–129. https://doi.org/10.1016/j.ejca.2019.12.021
doi: 10.1016/j.ejca.2019.12.021
pubmed: 32007712
Antonescu CR, Suurmeijer AJ, Zhang L et al (2015) Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol 39(7):957–967. https://doi.org/10.1097/PAS.0000000000000404
doi: 10.1097/PAS.0000000000000404
pubmed: 25723109
pmcid: 4465992
Ballestero MM, de Souza SF, Pacheco Neto R et al (2021) Pediatric skull base tumors: A management challenge. J Pediatr Neurosci 16(1):35. https://doi.org/10.4103/jpn.jpn_56_20
doi: 10.4103/jpn.jpn_56_20
pubmed: 34316306
pmcid: 8276951
Lopez-Nunez O, John I, Panasiti RN et al (2020) Infantile inflammatory myofibroblastic tumors: Clinicopathological and molecular characterization of 12 cases. Mod Pathol 33(4):576–590. https://doi.org/10.1038/s41379-019-0406-6
doi: 10.1038/s41379-019-0406-6
pubmed: 31690781
Coffin CM, Hornick JL, Fletcher CD (2007) Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 31(4):509–520. https://doi.org/10.1097/01.pas.0000213393.57322.c7
doi: 10.1097/01.pas.0000213393.57322.c7
pubmed: 17414097
Childress MA (2018) Understanding oncogenic tyrosine kinase fusion driven cancer: an investigation into inflammatory myofibroblastic tumor and the non-kinase fusion partner. [Thesis/Dissertation]. Vanderbilt University Institutional Repository
Butrynski JE, D’Adamo DR, Hornick JL et al (2010) Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 363(18):1727–1733. https://doi.org/10.1056/NEJMoa1007056
doi: 10.1056/NEJMoa1007056
pubmed: 20979472
pmcid: 3014292
Theilen TM, Soerensen J, Bochennek K et al (2018) Crizotinib in ALK+ inflammatory myofibroblastic tumors-Current experience and future perspectives. Pediatr Blood Cancer 65(4):10.1002/pbc.26920. https://doi.org/10.1002/pbc.26920
Ogata M, Hatachi Y, Ogata T, Satake H, Imai Y, Yasui H (2019) Effectiveness of crizotinib for inflammatory myofibroblastic tumor with ALK mutation. Intern Med 58(7):1029–1032. https://doi.org/10.2169/internalmedicine.1640-18
doi: 10.2169/internalmedicine.1640-18
pubmed: 30449794
Gros L, Dei Tos AP, Jones RL, Digklia A (2022) Inflammatory myofibroblastic tumour: state of the art. Cancers (Basel) 14(15):3662. Published 2022 Jul 27. https://doi.org/10.3390/cancers14153662
Alaggio R, Cecchetto G, Bisogno G et al (2009) Inflammatory myofibroblastic tumors in childhood. Cancer 116(1):216–226. https://doi.org/10.1002/cncr.24684
doi: 10.1002/cncr.24684